Is OKUR or ONCY more undervalued in 2026?

CirclFi compares OnKure Therapeutics, Inc. (OKUR) and Oncolytics Biotech Inc. (ONCY) using 13 institutional-grade valuation models. OKUR has a Quality of Company score of 5.6/10 while ONCY scores 3.4/10.

Which is a better buy — OKUR or ONCY?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do OKUR and ONCY valuations compare?

OKUR at $4.20 and ONCY at $1.04 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

OKUR vs ONCY Valuation Comparison 2026 — Intrinsic Value Analysis

OKUR

Pharmaceutical Preparations

OnKure Therapeutics, Inc.

Quality

5.6

out of 10

Value Trap

LOW

Price

$4.20

Last close

Models

11/13

Active

ONCY

Pharmaceutical Preparations

Oncolytics Biotech Inc.

Quality

3.4

out of 10

Value Trap

—

Price

$1.04

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	OKUR Fair Value	OKUR Upside	ONCY Fair Value	ONCY Upside
Bayesian DCF	Intrinsic	$3.02	-28.2%	$0.24	-77.2%
Earnings Power Value	Intrinsic	$7.86	+66.2%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$6.37	+51.7%	$0.16	-84.5%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for OKUR vs ONCY — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

OKUR vs ONCY — Which Stock Is More Undervalued?

OKUR scores higher with a 5.6/10 quality rating vs ONCY's 3.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing OnKure Therapeutics, Inc. (OKUR) and Oncolytics Biotech Inc. (ONCY) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

OKUR currently trades at $4.20 with a QOC of 5.6/10, while ONCY trades at $1.04 with a QOC of 3.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).